Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
CY

NASDAQ · CYTK

Cytokinetics, Incorporated

Healthcare · Biotechnology

$73.62

Down-$0.49 (-0.66%)

Updated Sep 11, 2026, 6:54 AM

SID Score

5.5/10

Composite research score

Smart Money

62/100

Neutral

Market cap
7.23B
P/E ratio
-9.7
Dividend yield
0.00%
52-week range
$47.22 – $88.31
Volume
1.44M
Avg. volume
2.02M

Price performance

CYTK price history

1M range · 20 trading sessions · Daily adjusted prices

CYTK closed at $73.62 after 20 trading sessions, up 0.23% for the selected period.

Last close
$73.62
Period change
+0.23%
Period low
$70.91
Period high
$79.20
Daily close
View OHLC price history
CYTK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$73.23$75.10$73.13$73.621.44M
Sep 9, 2026$74.31$74.89$73.52$74.111.42M
Sep 8, 2026$72.39$76.805$72.39$75.351.92M
Sep 4, 2026$73.04$74.01$72.255$72.721.14M
Sep 3, 2026$73.55$74.225$71.41$73.951.59M
Sep 2, 2026$71.90$73.70$70.42$71.931.61M
Sep 1, 2026$69.85$72.455$69.83$71.401.9M
Aug 31, 2026$71.54$71.79$69.31$70.913.08M
Aug 28, 2026$73.88$74.42$71.66$72.094.36M
Aug 27, 2026$78.84$79.1288$77.84$77.901.11M
Aug 26, 2026$77.91$79.875$76.70$79.201.24M
Aug 25, 2026$77.93$78.72$77.21$77.461.26M
Aug 24, 2026$77.20$77.99$75.65$77.091.21M
Aug 21, 2026$77.30$77.70$76.65$76.841.52M
Aug 20, 2026$77.36$77.62$76.14$77.181.65M
Aug 19, 2026$77.23$77.88$76.17$77.741.51M
Aug 18, 2026$75.57$76.81$74.76$76.101.65M
Aug 17, 2026$73.90$75.92$73.46$75.871.49M
Aug 14, 2026$72.70$74.26$72.12$74.131.76M
Aug 13, 2026$76.80$76.81$73.40$73.451.77M

Latest CYTK news

The latest Smart Investors Daily articles mentioning CYTK.

Stock researchCompany · Overview

CYTK research

Overview

Company profile and research snapshot.

Company profile

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$79.75
Implied upside
—
Analysts
—
CYTK recent ratings
DateFirmRatingTarget
Aug 31, 2026HC Wainwright & Co.Buy—
Aug 13, 2026JP MorganOverweight—
Aug 13, 2026BarclaysOverweight—
Aug 10, 2026Truist SecuritiesBuy—
Aug 7, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Cytokinetics to Participate in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.Cantor Global Healthcare Conference 2026: Fireside chat on Thursday, September 10, 2026 at 11:30 AM Eastern Time in New York, NY.Mor

Yahoo · Sep 1, 2026

Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued?

Cytokinetics (CYTK) is back in focus after presenting new Phase 3 data for aficamten in hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026, alongside plans for a supplemental FDA filing. Cytokinetics shares have been under pressure in recent weeks, with the 7 day share price return down 8.46% and the 30 day share price return down 8.06%, even as the stock posts a year to date share price gain of 14.87% and a 1 year total shareholder return of 42.91%. This suggests...

Yahoo · Sep 1, 2026

Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM

Cytokinetics (NasdaqGS: CYTK) reports positive Phase 3 results for aficamten (MYQORZO) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The trial is described as the first successful clinical study in this indication, with results presented at a major cardiology conference and published in leading medical journals. Cytokinetics plans to submit a supplemental New Drug Application seeking an expanded label for aficamten in non-obstructive hypertrophic...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By